Logo

Oxford University Hospitals NHS Foundation Trust (OUH)

Oxford University Hospitals NHS Foundation Trust (OUH) provides general hospital services for people in Oxfordshire and the neighbouring counties, and specialist services on a regional and national basis.

The Trust runs four teaching hospitals: the John Radcliffe Hospital, Churchill Hospital and Nuffield Orthopaedic Centre in Oxford, and the Horton General Hospital in Banbury. Together they support a population of around 800,000. In addition to Oxfordshire, a significant proportion of OUH’s patients come from Buckinghamshire, Berkshire, Gloucestershire, Wiltshire, Northamptonshire and Warwickshire. Many other patients come from further afield for specialist services.

The Trust, which has a CQC rating of ‘Good’  has:

  • 1,300 beds, including 100 for children
  • 67 wards
  • 44 operating theatres
  • More than 12,000 staff, including 3,800 nurses and midwives; 1,300 healthcare support workers; and 2,000 doctors

In 2014-15 the Trust’s turnover was £916 million. 

Specialisms
The Trust’s John Radcliffe Hospital is the Major Trauma Centre for the Thames Valley region following designation in April 2012. The Trust is also the designated Thames Valley centre for providing new-born intensive care support to the most severely ill or premature babies. In March 2012 its specialist unit received £2.8 million in Government funding to double the number of intensive care cots from 10 to 20. The John Radcliffe Hospital site also includes the Oxford Children’s Hospital, the Oxford Eye Hospital, and the Oxford Heart Centre.

The Churchill Hospital is the centre for cancer services and medical and surgical specialties including renal and transplant, oncology, dermatology, haemophilia, infectious diseases, and chest medicine. It also incorporates OCDEM (the Oxford Centre for Diabetes, Endocrinology and Metabolic Medicine).

The Nuffield Orthopaedic Centre has an international reputation for excellence in orthopaedics, rheumatology and rehabilitation. Specialist services include: children’s rheumatology, limb reconstruction, bone infection, spinal surgery, primary malignant bone tumours and sarcomas, neurological and neuromuscular disabilities.

Research Excellence
A Joint Working Agreement between the Trust and the University of Oxford provides the ability to share ideas and activities in the pursuit of excellence in patient care, research and education.  Existing university collaborations include ambitious research programmes, funded by the National Institute for Health Research (NIHR), and established through the Oxford Comprehensive Biomedical Research Centre (BRC) and at the Biomedical Research Unit (BRU) in musculoskeletal disease at the Nuffield Orthopaedic Centre.

Research themes of particular strength in Oxford are: cancer; cardiovascular science; diabetes, endocrinology and metabolism; infection and immunology; musculoskeletal science; neuroscience; and reproduction and development.

Here are some examples of how research at OUH is supporting the development of new treatments:

The Trust was chosen by NHS England as one of 11 new Genomic Medicine Centres to deliver the 100,000 Genomes Project. This project aims to transform healthcare by improving prediction and prevention of disease and diagnostic tests, and allow personalisation of drugs and other treatments. The first patients began being recruited in February 2015.

A joint Oxford and Leeds study led by OUH consultant Professor Derrick Crook received wide publicity after showing that the vast majority of C. difficile cases in hospital are isolated cases and have not been spread from other known cases of active infection.

The first patient to receive gene therapy for an incurable type of blindness was treated at the John Radcliffe Hospital as part of a trial in partnership with the University of Oxford. If the trial is successful, the advance could lead to the first-ever treatment for choroideraemia, a progressive form of genetic blindness.

Surgeons in Oxford were the first in the UK to successfully implant an electronic retina into the back of an eye. On 22 March 2012, Chris James became the first patient in the UK to receive this ground-breaking surgery as part of a clinical trial being carried out at John Radcliffe Hospital and King's College Hospital in London.

Chief Executive: Dr Bruno Holthof

Dr Bruno Holthof is the Chief Executive Officer (CEO) of Oxford University Hospitals Foundation Trust (OUH) as of October 2015.

OUH employs 12,000 staff across four hospital sites and 44 other locations. Before OUH, he was CEO of the Antwerp Hospital Network from January 2004 until September 2015. During this period, he transformed ZNA into the most profitable hospital group in Belgium.

Before becoming a CEO, he was a partner at McKinsey & Company. During this period, he served a wide range of healthcare clients in Europe and the United States and gained significant expertise in the areas of strategy, organization and operations.

Bruno Holthof is a member of the Board of Barco NV, a public listed company providing visualization solutions for professional markets, and a member of the Board of Bpost, the Belgian Post which is publicly listed since 2013.

Bruno Holthof holds an M.B.A. from the Harvard Business School and an M.D./Ph.D. from the University of Leuven.

© 2017 — The Shelford Group
Login

Keep up to date

Follow The Shelford Group on Twitter and our RSS Feed.

If you would like more information about the Shelford Group or to get in touch, please click here